Get the Stockscreener App
123.02
0.52%
-0.64
After Hours:
123.02
Neurocrine Biosciences Inc stock is traded at $123.02, with a volume of 1.83M.
It is down -0.52% in the last 24 hours and up +14.71% over the past month.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
See More
Previous Close:
$123.66
Open:
$122.46
24h Volume:
1.83M
Relative Volume:
1.24
Market Cap:
$12.18B
Revenue:
$2.41B
Net Income/Loss:
$305.80M
P/E Ratio:
41.70
EPS:
2.95
Net Cash Flow:
$492.20M
1W Performance:
+2.36%
1M Performance:
+14.71%
6M Performance:
-2.94%
1Y Performance:
-9.98%
1-Day Range:
$121.42
$123.92
1-Week Range:
$119.62
$125.63
52-Week Range:
$84.23
$157.98
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Name
Neurocrine Biosciences Inc
Sector
Phone
(858) 617-7600
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
123.02 | 11.89B | 2.41B | 305.80M | 492.20M | 2.95 |
|
HLN
Haleon Plc Adr
|
11.35 | 50.14B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
168.63 | 72.38B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.79 | 4.22M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.03 | 45.51B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.78 | 19.45B | 16.54B | -1.64B | 749.00M | -1.45 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-25 | Upgrade | Needham | Hold → Buy |
| Apr-14-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-29-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-24-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-13-23 | Resumed | Citigroup | Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-21-23 | Reiterated | Mizuho | Neutral |
| Jul-24-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Jul-06-23 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| May-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-14-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-22 | Initiated | UBS | Buy |
| Sep-26-22 | Initiated | Wells Fargo | Equal Weight |
| Jun-06-22 | Resumed | Jefferies | Buy |
| Mar-03-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-25-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-18-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-21 | Initiated | BMO Capital Markets | Underperform |
| Nov-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Aug-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-18-21 | Resumed | Goldman | Neutral |
| May-06-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-02-21 | Initiated | Raymond James | Outperform |
| Sep-30-20 | Initiated | The Benchmark Company | Hold |
| Aug-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-29-20 | Downgrade | Goldman | Buy → Neutral |
| Jun-09-20 | Initiated | Wedbush | Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-24-20 | Initiated | William Blair | Outperform |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Feb-05-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-13-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Aug-07-19 | Initiated | RBC Capital Mkts | Outperform |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-05-19 | Initiated | Guggenheim | Neutral |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-22-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Feb-06-19 | Reiterated | BofA/Merrill | Buy |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-13-18 | Initiated | Goldman | Buy |
| Nov-21-18 | Initiated | Canaccord Genuity | Buy |
View All
Neurocrine Biosciences Inc Stock (NBIX) Latest News
Huntington's Disease Society hosts Team Hope Walk in Tulsa Saturday - KTUL
Neurocrine Biosciences, Inc. (NBIX)’s M4 Agonist Shows Promise in Schizophrenia Phase 2 Trial, Phase 3 Launched - MSN
In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III - insights.citeline.com
Director Kevin Gorman Sells 9,613 Shares of Neurocrine Biosciences Inc (NBIX) - GuruFocus
Neurocrine Biosciences director sells shares worth $1.16 million By Investing.com - Investing.com India
Neurocrine Biosciences director sells shares worth $1.16 million - Investing.com
Neurocrine (NBIX) Reports Positive Phase 2 Results for Schizophr - GuruFocus
Taysha’s pivotal trial plans; Keros to stop work on PAH drug, lay off 45% of staff - Endpoints News
Nxera Pharma Notes Neurocrine Biosciences Presents New - GlobeNewswire
Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 - GlobeNewswire Inc.
Neurocrine (NBIX) Reports Positive Phase 2 Results for Schizophrenia Treatment | NBIX Stock News - GuruFocus
Neurocrine reports positive Phase 2 schizophrenia study results - Investing.com
Neurocrine reports positive Phase 2 schizophrenia study results By Investing.com - Investing.com UK
Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 - PR Newswire
Neurocrine Biosciences’ SWOT analysis: stock’s resilience amid market challenges - Investing.com Australia
How to Take Advantage of moves in (NBIX) - news.stocktradersdaily.com
Insider Decision Making Waves At Neurocrine Biosciences: CHARLES KEVIN GORMAN Exercises Options, Realizing $0 - Nasdaq
Neurocrine at RBC Conference: Growth and Strategic Insights - Investing.com
Transcript : Neurocrine Biosciences, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-20-2025 11 - marketscreener.com
Tourette Syndrome Treatment Market Detailed Analysis - openPR.com
Neurocrine Biosciences (NBIX) Shares Positive Results from Pedia - GuruFocus
Neurocrine reports quality of life gains in tardive dyskinesia study By Investing.com - Investing.com South Africa
Neurocrine Presents Encouraging New Data From Phase 4 Study Of Ingrezza In Tardive Dyskinesia - Nasdaq
Neurocrine reports lasting benefits of CRENESSITY in CAH study By Investing.com - Investing.com India
Neurocrine Biosciences Says Tardive Dyskinesia Treatment Improves Functional, Quality of Life Measures - marketscreener.com
Neurocrine reports quality of life gains in tardive dyskinesia study - Investing.com
Neurocrine reports progress for CAH drug as Voyager partnership shifts - The Pharma Letter
Neurocrine reports lasting benefits of CRENESSITY in CAH study - Investing.com
Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting - PR Newswire
Neurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia - WV News
Neurocrine Biosciences, Inc. (NBIX): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying - Insider Monkey
90% Success Rate: CRENESSITY Shows Breakthrough Results in Congenital Adrenal Hyperplasia | NBIX Stock News - Stock Titan
Neurocrine (NBIX) Highlights Risks of High Glucocorticoid Doses in CAH Patients | NBIX Stock News - GuruFocus
Neurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia - PR Newswire
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results - Longview News-Journal
New Research Reveals Dangerous Side Effects of High-Dose Steroids in CAH Treatment: What Doctors Need to Know - Stock Titan
15 Small-Cap Healthcare Stocks Hedge Funds Are Buying - Insider Monkey
Neurocrine at BofA Conference: Strategic Moves and Market Challenges - Investing.com
Learn to Evaluate (NBIX) using the Charts - news.stocktradersdaily.com
Neurocrine Biosciences, Inc. (NBIX): Among Billionaire Ken Griffin’s Midcap Stock Picks with Huge Upside Potential - Insider Monkey
Neurocrine Biosciences To Present BofA Securities 2025 Health Care Conference; Webcast At 2:20 PM ET - Nasdaq
Crinecerfont Reduces Steroid Use for Pediatric CAH in Phase 3 Analysis - HCPLive
Cognitive Impairment Associated with Schizophrenia Pipeline - openPR.com
Cognitive Impairment Associated with Schizophrenia Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Cyclerion Therapeutics, Biogen, Neurocrine - Barchart.com
Investors Can Find Comfort In Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Quality - Yahoo Finance
Earnings Tell The Story For Neurocrine Biosciences, Inc. (NASDAQ:NBIX) As Its Stock Soars 27% - simplywall.st
Wedbush Lifts Earnings Estimates for Neurocrine Biosciences - Defense World
Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma - insights.citeline.com
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $160.00 - Defense World
Wedbush Forecasts Lower Earnings for Neurocrine Biosciences - Defense World
Neurocrine Biosciences First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st
Neurocrine Biosciences Inc Stock (NBIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.22%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):